Vimian Group AB (publ) (FRA:0V0)

Market Cap	1.96B +24.1%
Revenue (ttm)	466.90M +10.9%
Net Income	39.20M +24.4%
EPS	0.07 +16.5%
Shares Out	n/a
PE Ratio	49.72
Forward PE	26.05
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31
Open	3.545
Previous Close	3.395
Day's Range	3.545 - 3.545
52-Week Range	2.246 - 3.545
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 22, 2026

About Vimian Group AB

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 1,300
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0V0

Financial Performance

In 2025, Vimian Group AB's revenue was 425.10 million, an increase of 13.42% compared to the previous year's 374.80 million. Earnings were 31.30 million, an increase of 69.19%.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error